Metastatic extramammary Paget’s disease treated with paclitaxel and trastuzumab combination chemotherapy
- 30 July 2009
- journal article
- case report
- Published by Wiley in The Journal of Dermatology
- Vol. 36 (8), 457-461
- https://doi.org/10.1111/j.1346-8138.2009.00676.x
Abstract
In the treatment of metastatic breast cancer, trastuzumab, a recombinant monoclonal antibody against human epidermal growth factor receptor 2 (HER2), is effective when tumor cells overexpress HER2 protein. Although some cases of extramammary Paget's disease (EMPD) also express HER2 protein, no case of EMPD has been reported to be treated with trastuzumab. A 75-year-old man who suffered from EMPD of the scrotum and inguinal region underwent a local excision and lymph node dissection. Tumor cells invaded the dermis and lymph nodes. Although he was postoperatively treated with adjuvant chemotherapies, metastatic skin lesions appeared and spread over his left thigh, rapidly and widely. Tumor cells disseminated along lymph vessels in the dermis and overexpressed HER2 protein. We administered paclitaxel and trastuzumab according to a protocol for HER2-positive metastatic breast cancers. The skin metastasis dramatically decreased during the regimen and a histopathological examination showed that most of HER2-positive tumor cells diminished. Six months later, metastases were found in the central nervous system (CNS), but no other metastases were found in the skin, visceral organs or lymph nodes. Trastuzumab and paclitaxel-combination with the assessment of central nervous system lesions should be considered as an option for the treatment of HER2-positive EMPD.Keywords
This publication has 7 references indexed in Scilit:
- Clinical Efficacy of Taxane–Trastuzumab Combination Regimens for HER-2–Positive Metastatic Breast CancerThe Oncologist, 2008
- Brain Metastases: The HER2 ParadigmClinical Cancer Research, 2007
- Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancerThe Breast, 2006
- Extramammary Paget's disease: analysis of growth signal pathway from the human epidermal growth factor receptor 2 proteinHuman Pathology, 2005
- Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinomaCancer, 2003
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- erbB-2 Overexpression But No Activation of β-Catenin Gene in Extramammary Paget's DiseaseJournal of Investigative Dermatology, 1999